Scientific American3d agoWhy the FDA rejected a ‘breakthrough’ melanoma drugThe FDA rejected the promising skin cancer drug RP1 twice, leaving many puzzled and worried about what this means for other drug approvalsRead at Scientific AmericanTagsmedicineoncologypharmacology
